Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.

Prentice, Ralley E; Al-Ani, Aysha H; Bond, Katherine; Johnson, Doug; Christensen, Britt

Prentice, Ralley E; Al-Ani, Aysha H; Bond, Katherine; Johnson, Doug; Christensen, Britt.

Prentice RE; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
Al-Ani AH; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
Bond K; Department of Infectious Diseases, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
Johnson D; Department of Infectious Diseases, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
Christensen B; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia. Electronic address: britt.christensen@mh.org.au.

Dig Liver Dis ; 52(11): 1250-1251, 2020 11.

Article in English | MEDLINE | ID: covidwho-770869

Subject(s)

Coronavirus Infections; Inflammatory Bowel Diseases; Pandemics; Pneumonia, Viral; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Biological Therapy/adverse effects; COVID-19; Humans; Immunization; Inflammatory Bowel Diseases/diagnosis; Inflammatory Bowel Diseases/drug therapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Inflammatory Bowel Diseases / Coronavirus Infections / Severe acute respiratory syndrome-related coronavirus / Pandemics Type of study: Diagnostic study Limits: Humans Language: English Journal: Dig Liver Dis Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: J.dld.2020.08.035

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google